Stefan Szedlacsek, Dr.

Stefan Szedlacsek
Group: Enzymology
Department: Enzymology

Head of Department

Research interests: TBA, Researcher | Teaching staff | Scientific reviewer | Manager | Consultant.

Currently working on

Institute of Biochemistry of the Romanian Academy , Bucharest.
Department of Enzymology .

Biography

Prof. Dr. Stefan Szedlacsek is the Head of the Enzymology Department at the Institute of Biochemistry of the Romanian Academy. He holds a PhD degree in Biotechnology from Polytechnical University of Bucharest as well as a MSc in Organic Synthesis (Polytechnical University, Bucharest) and MSc in Mathematics (University of Bucharest). As a visiting scientist, he performed research in the field of cholesterol metabolism at the University of Illinois at Urbana-Champaign (USA), where he succeeded to evidence a new pathway in the metabolism of oxysterols. 

He is an “Alexander von Humboldt” fellow and worked in Germany, in the Institute of Biochemistry (Kiel University), Max-Plack Institute for Physiological Chemistry (Dortmund) and Max-Planck Institute for Biophysics (Frankfurt).

Between August 2022-February 2023, he was a Fulbright Visiting Scholar at MD Anderson Cancer Center- University of Texas, Department of Leukemia, where his research title was “Biochemical and cellular investigations regarding the potential use of affibodies in leukemia therapy” (Grant no:779/06.06.2022).

He has supervised numerous PhD and master’s theses. Together with his group, he participated as Principal Investigator/Group Leader in the Marie Curie Research Training Networks - PTPNET; MRTN-CT- 2006-035830 (FP6), financed by the European Community. Also, he received a „P-CUBE TNA Project” Fellowship (FP 7- EU) from Oxford University (United Kingdom). Professor Szedlacsek was Project Coordinator for research consortia within a number of projects financed by the Romanian Research Authority.

Together with his group, he is dedicated to the study of structure-function relationships in the enzymes involved in cell signaling, especially in the protein tyrosine phosphatases (PTP). He succeeded to solve the first crystal structure of a member of KIM-containing family of PTP,  evidenced that MAM domain of receptor PTPμ promotes lateral dimerization, identified molecular determinants of PRL3, a molecular marker of various cancer forms and solved the crystal structure of xylulose-5 phosphate phosphoketolase. Several years ago, he reported identification of WDR1 as a novel substrate of EYA3 PTP and proved that WDR1 dephosphorylation modulates the actin cytoskeleton.

Papers

Year
View all papers

Grants

Compound for inhibition of certain signaling processes related to the evolution of the cognitive processes 2017-2018
Acronym: Ctr.327/27.03.2017/Company CRU SRL, Medical Services Company/ Dunakesz, Hungary
Project director: Stefan Szedlacsek

The main idea of this project was that by inhibiting at least one of these two interactions of GluA2, the internalization of AMPAR will be reduced and therefore the synapse resistance will be increased, thus leading to improved cognitive functions.

Compound for inhibition of certain signaling processes related to the evolution of the cognitive processes
Novel radiolabeled affibodies for targeted imaging and therapy 2019-2022
Acronym: Bilateral agreement no.3698/13.09.2018 Romanian Academy- Hungarian Academy of Sciences
Project director: Stefan Szedlacsek

The project is agreed as a bilateral collaboration between IBAR and ATOMKI, and the University of Debrecen and IFIN-HH participate in this project voluntarily.

Radiolabelling of affibody for tumor diagnostic and theranostic application in the nuclear medicine 2022-2024
Acronym: Bilateral agreement no.2886/15.09.2021 Romanian Academy- Hungarian Academy of Sciences
Project director: Stefan Szedlacsek

The project is agreed as a joint collaboration among IBAR, ATOMKI and UD, the latter being a cost free participant. There are two main directions envisaged by the proposed project: - receptors mapping and therapy, using an affibody against HER2 receptors, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establishing labelling procedures; c) ex vivo and/or in vivo testing of optimal compounds.

Biochemical and cellular investigations on the potential use of affibodies in leukemia therapy 2022 - 2023
Acronym: LEUKEMIA. Grant no.779/14.06.2022
Project director: Stefan Szedlacsek

Affibody molecules are highly promising therapeutic candidates due to their advantageous features like: small size, efficient delivery, straightforward engineering towards improved formats, site-directed conjugation of payloads, possibility of GMP production by chemical synthesis or inexpensive bacterial production leading to low product costs.

Biochemical and cellular investigations on the potential use of affibodies in leukemia therapy
Protein Tyrosine Phosphatases: Structure, regulation and biological function 2007 - 2011
Acronym: PTPNET
Project director: Stefan Szedlacsek

Project Funded under: Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006. PTPNET was a Training Network for young scientists in the field of protein tyrosine phosphatase (PTP) research.

Reconstruction of Ancestor of Receptor Protein Tyrosine Phosphatase Catalytic 2011 - 2016
Acronym: PTPs
Project director: Stefan Szedlacsek

Proteins are essential players of all biological processes and they are involved in practically every function performed by a living cell.

Structural insights into three domains of PTP-Basophil-like protein tyrosine phosphatase 01.10.2005 - 30.09.2009
Acronym: PTP-BL
Budget: 50.000 €
Project director: Stefan Szedlacsek

The Alexander von Humboldt Foundation promotes academic cooperation between foreign and German researchers at the highest level. Each year, the Foundation awards more than 700 research fellowships and awards to support researchers from abroad who come to Germany to work on a research project together with German researchers at a host institute. The research topic is chosen by the applicant.

Structural and Kinetic analysis of the functional complex between protein tyrosine phophatase SL (PTP-SL) and Erk2 MAP kinase 2004 - 2008
Acronym: PTP-SL
Project director: Stefan Szedlacsek

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is the most important independent research funding organisation in Germany. It supports both scientific and humanistic studies and aims to promote top-level research in various disciplines at universities and research institutions. The main focus is on funding projects proposed by the scientific community, with an emphasis on knowledge-driven research.